Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 11

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 11
---
 Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification
Letter to evidence compliance.

We are looking into various
options available to regain compliance and maintain our continued listing on The Nasdaq Capital Market. There can be no assurance that
our plan will be accepted or we will be able to regain compliance with the Minimum Stockholders’ Equity Rule.

<div align='center'>3</div>

As previously announced, on September 17,
2025, we entered into securities purchase agreements, or the SPAs, with investors, or the CLA Investors, pursuant to which we shall
issue and sell, from time to time, convertible promissory notes, or the Promissory Notes, in the aggregate principal amount of up to
$10,000,000, or the Subscription Amount. We had issued Promissory Notes in the aggregate principal amount of
$2.5 million. As of the date hereof, all the outstanding amounts due under the Promissory Notes were converted into
5,171,460 Common Shares. In addition, on November 13, 2025, we raised approximately $0.788 million in a registered direct offering
of common shares and pre-funded warrants, on November 17, 2025, we raised approximately $1.377 million in a registered direct
offering of common shares and pre-funded warrants and on November 19, 2025, we raised approximately $2.185 million in a registered
direct offering of common shares (see “Recent Developments—November 2025 Registered Direct Offerings” below for
additional information), and as of November 14, 2025, we issued 2,090,987 common shares as a result of the exercises for cash and on
a cashless basis of warrants to purchase 2,894,769 common shares, which were previously classified as a liability given certain of
their contractual terms which precluded equity classification, that were issued in our financings in April 2023, and January 2024
for aggregate gross proceeds of approximately 183,000 (see “Recent Developments—Warrant Exercises” below for
additional information). We expect that we will be able to demonstrate compliance with the Nasdaq stockholders’ equity
requirement as a result of such financing and warrant exercises.

November 2025 Registered Direct Offerings

On November 13, 2025, we entered
into a securities purchase agreement with investors for the purchase and sale of (